Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI])
NCT02414633 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 148
Last updated 2018-10-16
Summary
A special investigation (post marketing observational study \[PMOS\]/non-mandatory) of HUMIRA® in Japanese psoriatic arthritis patients who are engaged in paid work.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Sarina Kurimoto, MD · AbbVie
Eligibility
- Min Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-04-01
- Primary Completion
- 2017-03-13
- Completion
- 2017-03-13
More Related Trials
-
A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment
NCT02897115 ·Status: TERMINATED ·Phase: PHASE4
-
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
NCT01076205 ·Status: COMPLETED
-
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
NCT01282372 ·Status: COMPLETED
-
A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis
NCT02627768 ·Status: COMPLETED
-
A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis
NCT00963313 ·Status: COMPLETED
-
Drug Use Investigation for Humira® - All Patient Investigation for Rheumatoid Arthritis
NCT01076959 ·Status: COMPLETED
-
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
NCT01474876 ·Status: COMPLETED
-
HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
NCT02916017 ·Status: COMPLETED
-
Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement
NCT04062695 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)
NCT02349451 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis
NCT04713072 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis
NCT00646386 ·Status: COMPLETED ·Phase: PHASE2
-
ToFAcitinib in Early Active Axial SpondyloarThritis:
NCT06112665 ·Status: RECRUITING ·Phase: PHASE4
-
Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice
NCT01754727 ·Status: COMPLETED
-
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
NCT01490450 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Humira in Behcet Patients With Arthritis
NCT01497717 ·Status: COMPLETED ·Phase: PHASE3
-
A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )
NCT01078558 ·Status: COMPLETED
-
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
NCT02720523 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)
NCT01079182 ·Status: COMPLETED
-
Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis
NCT00234897 ·Status: COMPLETED ·Phase: PHASE4
-
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
NCT01083693 ·Status: COMPLETED
-
Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis
NCT00051662 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
NCT06100744 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis
NCT02251210 ·Status: COMPLETED ·Phase: PHASE2
-
Characterizing Spondyloarthritis With 68Ga-FAPI PET/CT
NCT05999643 ·Status: UNKNOWN ·Phase: NA